LC
CBMG

Lindbrook Capital’s Cellular Biomedicine Group, Inc. CBMG Stock Holding History

Lindbrook Capital’s Portfolio CBMG Stock Details CBMG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-50
Closed -$1K – 1925
2020
Q3 		$1K Buy
+50
New +$840 ﹤0.01% 1718

Other funds holding CBMG

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Man Group
Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Lindbrook Capital's CBMG Position: Q4 2020 in Review

Lindbrook Capital sold out of Cellular Biomedicine Group, Inc. (CBMG) in Q4 2020, closing a stake of 50 shares — an estimated $1K sold.

Lindbrook Capital first reported a position in CBMG in Q3 2020 and held it in 1 quarter. The position peaked at $1K in Q3 2020. 67 funds tracked by Wall St. Rank hold CBMG as of Q4 2020.

  • Lindbrook Capital reported no remaining Cellular Biomedicine Group, Inc. position as of Q4 2020 after selling out during the quarter.
  • Lindbrook Capital sold 50 Cellular Biomedicine Group, Inc. shares in Q4 2020, an estimated $1K.
  • Lindbrook Capital first reported a position in Cellular Biomedicine Group, Inc. in Q3 2020 and held it in 1 quarter.
  • Lindbrook Capital's Cellular Biomedicine Group, Inc. position peaked at $1K in Q3 2020.
  • 67 funds tracked by Wall St. Rank held Cellular Biomedicine Group, Inc. as of Q4 2020.

Based on Lindbrook Capital's 13F filing for Q4 2020, filed 27 Jan 2021.